Actually the partnership came together the other way round: the "comparatively tiny startup" saw articles about SARS-CoV-2, decided to start sketching out a vaccine, called Pfizer, which they had prior business relations due to joint work on previous projects, asked whether they'd be interested in jointly develop this new vaccine, and Pfizer's head of vaccine research said "yeah, sure!" immediately.